On August 20, 2025, Lyra Therapeutics, Inc. received a deficiency letter from Nasdaq due to its stockholders' equity being approximately $1.6 million, which is below the required $2.5 million. The company has until October 4, 2025, to submit a plan to regain compliance to avoid potential delisting.